Back to search results

Digital Mind Body Intervention for Black and Hispanic Patients with IBD

This study is testing a mobile app called "Digital Mind Body Intervention" (DMBI) for Black and Hispanic patients living with Crohn's disease or ulcerative colitis (types of inflammatory bowel disease or IBD). The app aims to help with psychological distress, which can affect IBD symptoms. Researchers want to see if the app is easy to use, if people will stick with it, and if they complete the program. You might be able to join if you are at least 18 years old, identify as Black/African American and/or Hispanic/Latino(a/x), have Crohn's disease or ulcerative colitis, can give informed consent in English, and have elevated psychological distress. The study plans to enroll 40 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 40 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Feasibility, retention, and adherence to the DMBI mobile application will be measured at 8 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06510296

Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease

Not Yet Recruiting
NAAges 18+InterventionalSupportive care
Montefiore Medical Center
~40 participants
Updated 2026-06-17 on ClinicalTrials.gov
What's tested:Digital Mind Body Intervention mobile application

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility - DMBI recruitment rate
Measured over 8 weeks
+2 more outcomes measured

Conditions

Crohn's Disease
Ulcerative Colitis
Inflammatory Bowel Diseases

Explore related trials

Crohn DiseaseUlcerative Colitis

Where it's being run

1 sites across 1 states
New York1

Study leadership

  • Ruby Greywoode, MD · PRINCIPAL_INVESTIGATOR · Montefiore Medical Center

Who to contact

Ruby Greywoode, MD
[email protected]
347-671-8211
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

age ≥ 18 years
self-identify as Black/African American and/or Hispanic/Latino(a/x)
diagnosed with Crohn's disease or ulcerative colitis
ability to provide informed consent in English
elevated psychological distress: at least one T-score within 2.5 standard deviations above the mean -- NIH Toolbox Perceived Stress Scale or in the domains of either Anxiety or Depression on the NIH PROMIS-29.

Exclusion

Anxiety, depression, or perceived stress T-scores above 2.5 standard deviations above the mean.
Current suicidality, past suicide attempt, or psychiatric hospitalization.

What this trial measures

  • Feasibility - DMBI recruitment rate8 weeks

    DMBI recruitment rate will be determined by the proportion of eligible patients who enroll into the trial. A benchmark to define this feasibility outcome will be ≥ 30% of eligible patients enrolling.

  • Feasibility - DMBI retention rate8 weeks

    DMBI Retention rate will be determined by the proportion of enrolled patients who complete all DMBI modules. A benchmark to define this feasibility outcome will be ≥ 70% of enrolled patients completing all DMBI modules.

  • Feasibility - DMBI adherence8 weeks

    DMBI adherence will be assessed by the percentage of completed activities per module will be determined. A benchmark to define this feasibility outcome will be ≥ 50% of completed activities per module.